Chinese biopharmaceutical firm Adlai Nortye bags $100m in a Series D round

Hangzhou Adlai Nortye Biopharma Co., Ltd, a Chinese clinical-stage biopharmaceutical firm that makes immuno-oncology medicines, has raked in $100 million in a Series D round, according to a company statement on Tuesday ... In August last year, Adlai Nortye had completed a similar-sized Series C round funding jointly led by Tigermed and Shanghai-based asset manager Yingke PE with participation from investors such as ICBC’s overseas investment arm ICBC Asset Management, and ATCG Holdings ... The lead investor CMG-SDIC Capital had also co-led over 400 million yuan ($62 million) in a Series C round funding in biopharmaceutical firm Juventas Cell Therapy on July 12.